Conway Stuart Stretta GERD Clearance Expected By April 2000
This article was originally published in The Gray Sheet
Conway Stuart's Stretta radiofrequency ablation catheter and control module could gain 510(k) approval for the treatment of gastroesophageal reflux disease (GERD) as early as April 2000, company founder Stuart Edwards reported Oct. 28.
You may also be interested in...
Advanced UroScience's post-approval study of its Durasphere bulking agent for treatment of female stress urinary incontinence due to intrinsic sphincter deficiency will focus on evaluating the durability of the product, the company reports.
Bard expects to add roughly $5 mil. to its top line during the first year of sales of its endoscopic suturing device for treatment of severe gastroesophageal reflux disease (GERD).
Aker BioMarine seeks supplement firms to use its EPA/DHA innovation bound by lysophosphatidylcholine to enable the fatty acids to pass through the blood-brain and blood-retinal barriers and boost of eye and brain health benefits. It will submit an NDI notificaion in the US during 2022.